erpes zoster ophthalmicus (HZO) results from reactivation of latent varicella-zoster virus (VZV) in the ophthalmic division of the trigeminal ganglion. Anterior uveitis (AU) is a well-described complication of HZO. Since becoming available in 1995, the live VZV vaccine Zostavax (Merck and Co, Inc) has successfully decreased VZV reactivation. Consequently, the Centers for Disease Control and Prevention recommend that all appropriate adults aged 60 years and older receive Zostavax, and prior HZO is not a contraindication to vaccination.
nation, the patient had visual acuity of 20/200 OD, decreased from his baseline of 20/40 OD. Examination showed worsened corneal edema, centrally located KPs in a linear distribution, and 1ϩ cells and flare in the anterior chamber. The presence of corneal edema and KPs not localized in the Arlt triangle, normal intraocular pressure, and mild anterior chamber cells suggest recurrent endotheliitis. No corneal epithelial or inflammatory stromal involvement was observed. The patient was treated with valacyclovir hydrochloride, 1 g 3 times per day for 7 days, and intensive topical prednisolone therapy, resulting in return to his baseline condition.
Comment. This is a case of an adult patient initially manifesting HZO AU and endotheliitis and then experiencing a uveitis exacerbation that was significant for worsening corneal edema attributed to AU and endotheliitis and temporally associated with Zostavax administration. Because the patient had not previously experienced an exacerbation with KPs and corneal decompensation as occurred after receiving the vaccine, this temporal association suggests that his exacerbation was due to the vaccine.
A single prior case report describes VZV ocular disease, specifically interstitial keratitis, in an adult patient 35 days after vaccination, 2 and a few pediatric cases of uveitis after administration of a live attenuated VZV vaccine have also been reported. [3] [4] [5] This case adds to the literature suggesting risk of ocular inflammation recurrence after VZV vaccination. While isolated case reports are insufficient to conclude that AU is a contraindication to VZV vaccination, we advise caution in vaccinating patients with a history of HZO. 
Impact of Availability of Anti-Vascular Endothelial Growth Factor Therapy on Visual Impairment and Blindness Due to Neovascular Age-Related Macular Degeneration
A nti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular age-related macular degeneration (AMD).
1,2 Recent theoretical modeling suggests that monthly anti-VEGF therapy may dramatically decrease the incidence of blindness due to AMD in this country. 3 We describe 2 cohorts of patients with incident neovascular AMD in the last decade, selected to have 1 cohort before and 1 after the advent of anti-VEGF therapy to explore whether there are data to support the theoretical model in a clinical practice setting. Table shows the 2-year prevalence of legal blindness, mild and moderate visual impairment in both cohorts, the 2-year prevalence of visual impairment in the study eye, and the relative odds of outcomes adjusted for age, gender, and baseline VA in the study eye.
Comment. This study confirms that the prevalences of legal blindness and moderate visual impairment 2 years following the diagnosis of neovascular AMD have decreased substantially following the introduction of anti-VEGF therapy. These data correspond well to theoretical modeling data previously published. 3 There are several limitations inherent to this retrospective cohort study, including the unknown effect of the exclusion of patients who did not have continued follow-up and use of a cohort from a tertiary academic-based center. Nonetheless, the results suggest that despite the increasing prevalence of neovascular AMD, the prevalence of blindness due to neovascular AMD is decreasing provided that the stabilization in VA between 12 and 24 months is maintained thereafter. 
